Literature DB >> 7875188

Early stage autoinduction of carbamazepine metabolism in humans.

I Bernus1, R G Dickinson, W D Hooper, M J Eadie.   

Abstract

Six healthy young adult male volunteers were given two 600 mg (2540 mu moles) oral doses of carbamazepine (CBZ) 5 days apart. Serial concentrations of CBZ and its 10,11-epoxy (CBZ-epoxide) and 10,11-dihydro-10,11-trans-dihydroxy (CBZ-diol) metabolites in plasma, and daily excretions of these substances and the 2-hydroxy (2-OH-CBZ), 3-hydroxy (3-OH-CBZ) and 9-hydroxymethyl-10-carbamoylacridan (acridan) metabolites in urine were followed for 5 days after each dose. Pharmacokinetic analysis showed that autoinduction of CBZ metabolism was present within 6-10 days of the initial drug dose. The mean oral clearance of CBZ increased from 1.48 to 1.74 l.h-1 (difference 0.26 l.h-1, 95% confidence interval 0.11 to 0.41 l.h-1) and the mean percentage urinary recovery of the amount of CBZ eliminated increased from 41.8% to 44.6% (difference 2.8%, 95% confidence interval 0.5 to 5%) between the two studies 5 days apart. The data for daily clearance to metabolite and the time-courses of the plasma CBZ-epoxide to CBZ and CBZ-diol to CBZ concentration ratios suggested that autoinduction had begun by the second day after CBZ intake, and involved not only the epoxide-diol pathway but, to a lesser extent, the oxidations to phenolic derivatives.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7875188     DOI: 10.1007/bf00191168

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Pharmacokinetics of carbamazepine-10,11- epoxide before and after autoinduction in rhesus monkeys.

Authors:  I H Patel; R H Levy; W F Trager
Journal:  J Pharmacol Exp Ther       Date:  1978-09       Impact factor: 4.030

2.  Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine.

Authors:  W H Pitlick; R H Levy; A S Tropin; J R Green
Journal:  J Pharm Sci       Date:  1976-03       Impact factor: 3.534

3.  Confidence intervals rather than P values: estimation rather than hypothesis testing.

Authors:  M J Gardner; D G Altman
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-15

4.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

5.  Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors:  M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

7.  Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine.

Authors:  W G Rapeport; G T McInnes; G G Thompson; G Forrest; B K Park; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

8.  Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.

Authors:  T B Kudriakova; L A Sirota; G I Rozova; V A Gorkov
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

9.  Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children.

Authors:  B F Bourgeois; N Wad
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

10.  Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique.

Authors:  L Bertilsson; B Höjer; G Tybring; J Osterloh; A Rane
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

View more
  3 in total

1.  Characterization of the time course of carbamazepine deinduction by an enzyme turnover model.

Authors:  Baralee Punyawudho; James C Cloyd; Ilo E Leppik; R Eugene Ramsay; Susan E Marino; Page B Pennell; James R White; Angela K Birnbaum
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring--antiepileptic drugs.

Authors:  M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

Review 3.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.